BUX — BioMark Diagnostics Income Statement
0.000.00%
Last trade - 00:00- CA$26.27m
- CA$26.73m
- CA$0.16m
Annual income statement for BioMark Diagnostics, fiscal year end - March 31st, CAD millions except per share, conversion factor applied.
2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | ARS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0.263 | 0 | 0.044 | 0.153 | 0.163 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Other Operating Expenses | |||||
| Total Operating Expenses | 1.49 | 1.08 | 1.45 | 2.09 | 1.78 |
| Operating Profit | -1.22 | -1.08 | -1.4 | -1.93 | -1.61 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -1.22 | -1.09 | -1.45 | -1.84 | -1.43 |
| Net Income After Taxes | -1.22 | -1.09 | -1.45 | -1.84 | -1.43 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -1.22 | -1.09 | -1.45 | -1.84 | -1.43 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -1.22 | -1.09 | -1.45 | -1.84 | -1.43 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.017 | -0.015 | -0.021 | -0.022 | -0.017 |